Skip to main content

COVID-19: A Message from Our CEO

Paul Perreault

"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities can continue to deliver on our promise to patients and public health."

Paul Perreault, CEO and Managing Director, CSL Limited

CSL Behring’s Global Role in Battling Coronavirus

Here is how CSL Behring is working around the world with academia, industry and governments to combat COVID-19.

  • CSL Behring is part of the CoVIG-19 Plasma Alliance, an unprecedented industry partnership to develop a potential plasma-derived therapy for treating COVID-19. The CoVIg-19 Plasma Alliance is developing an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine for treating hospitalised adults at risk for serious complications of COVID-19 disease.

  • The CoVIg-19 Plasma Alliance, which includes CSL Behring, has joined the The Fight Is In Us campaign — a coalition of world-leading medical and research institutions, blood centres, life science companies, technology companies, philanthropic organisations, and COVID-19 survivor groups brought together to support rapid development of potential new therapies for patients with COVID-19.

  • CSL Behring Australia is developing an anti-SARS-CoV-2 plasma product for the Australian market with potential to treat people with serious complications of COVID-19, particularly those whose illness is progressing towards the need for ventilation. The investigational product, to be known as COVID-19 Immunoglobulin, is under development at the company’s advanced manufacturing facility located in Broadmeadows, Victoria.

  • CSL and AstraZeneca have agreed for CSL to manufacture about 30 million doses of the Oxford University vaccine candidate AZD1222, for supply to Australia.      

  • Launching a clinical trial into the use of CSL312 (garadacimab, Factor XIIa antagonist monoclonal antibody) to treat patients suffering from severe respiratory distress, a leading cause of death in patients with COVID-19 related pneumonia.

  • Partnering with SAB Biotherapeutics, a clinical-stage biopharmaceutical company, to advance and deliver a novel immunotherapy targeting COVID-19. The potential therapy would be produced without the need for blood plasma donations from recovered COVID-19 patients.

  • Additionally, from the time the coronavirus was first identified in Wuhan, China – where CSL Behring has a manufacturing facility – the company has been assisting in the fight against COVID-19 by offering expertise, technologies, equipment and materials on a humanitarian basis.

GBR-CRP-0116 February 2021